• Filgotinib demonstrates durable efficacy and consistent safety profile at 52 weeks in Finch 1 and 3 studies in rheumatoid arthritis

    Thursday June 4th 2020

  • Celyad provides update on allogeneic CAR-T franchise

    Tuesday June 2nd 2020

  • argenx announces positive topline results from Phase 3 ADAPT Trial of Efgartigimod in patients with Generalized Myasthenia Gravis

    Tuesday May 26th 2020

  • Gilead and Galapagos announce positive topline results of Phase 2B/3 trial of Filgotinib

    Thursday May 21st 2020

  • Bone Therapeutics treats first patients in pivotal JTA-004 phase III knee osteoarthritis study

    Monday May 18th 2020

  • Progressing clinical development of next generation therapies for Diabetic eye disease – beyond anti-VEGF

    Friday May 8th 2020

  • Galapagos: On track for clinical read-outs

    Friday May 8th 2020

  • VIB’s efforts in COVID-19 testing

    Thursday May 7th 2020

  • Your news here?

  • Biotalys’ first biocontrol proves consistent, high efficacy in global fruit and vegetables field trial program

    Wednesday May 6th 2020

  • Towards antibodies against COVID-19

    Wednesday May 6th 2020

  • Biocartis announces development of Idylla™ COVID-19 test

    Thursday April 23rd 2020


Strategic Partners